Prognostic performance of pretreatment systemic immune-inflammation index in women with epithelial ovarian cancer-Reference-Cited by-同舟云学术

Prognostic performance of pretreatment systemic immune-inflammation index in women with epithelial ovarian cancer

Published:2023-12 Issue:10 Volume:9 Page:
ISSN:2056-5623
Container-title:Future Science OA
language:en
Short-container-title:Future Science OA

Author:

Okunade Kehinde S¹²³^ORCID,John-Olabode Sarah O⁴^ORCID,Soibi-Harry Adaiah P²^ORCID,Okoro Austin C²,Adejimi Adebola A⁵^ORCID,Ademuyiwa Iyabo Y⁶^ORCID,Osunwusi Benedetto²^ORCID,Adelabu Hameed³,Salako Omolola⁷^ORCID

Affiliation:

1. Department of Obstetrics & Gynaecology, College of Medicine, University of Lagos, Surulere, Lagos, Nigeria

2. Department of Obstetrics & Gynaecology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria

3. Center for Clinical Trial, Research, & Implementation Science (CCTRIS), College of Medicine, University of Lagos, Lagos, Nigeria

4. Department of Haematology & Blood Transfusion, College of Medicine, University of Lagos, Lagos, Nigeria

5. Department of Community Health & Primary Care, College of Medicine, University of Lagos, Lagos, Nigeria

6. Department of Nursing Science, College of Medicine, University of Lagos, Lagos, Nigeria

7. Department of Radiation Biology, Radiotherapy & Radiodiagnosis, College of Medicine, University of Lagos, Lagos, Nigeria

Abstract

Purpose: This study investigated the prognostic performance of the systemic immune-inflammation index (SII) in patients with epithelial ovarian cancer (EOC) in Lagos, Nigeria. Methods: We performed a secondary analysis of the data of 91 women who had treatment for EOC between 2009 and 2018. The associations between pretreatment SII and survivals were tested. Results: Pretreatment SII more than 610.2 was a significant independent predictor of reduced progression-free survival (HR = 2.68; 95% CI, 1.17 to 6.09) while SII greater than 649.0 was a significant independent predictor of reduced 3-year overall survival (HR = 2.01; 95% CI, 1.01 to 3.99). Conclusion: These findings suggest that high SII may be a potential prognostic indicator and useful marker for more intensive surveillance and design of personalized treatment in patients with EOC.

Funder

Fogarty International Center

Publisher

Future Science Ltd

Subject

Biotechnology

Link

https://www.future-science.com/doi/pdf/10.2144/fsoa-2023-0108

Reference32 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Cancer statistics, 2023

3. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer

4. Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival outcomes following interval versus primary debulking surgery in advanced epithelial ovarian cancer: A retrospective cohort study in Lagos, Southwest Nigeria;2024-01-05

2. Prognostic Significance of Preoperative Inflammation Markers on the Long-Term Outcomes in Peritoneal Carcinomatosis from Ovarian Cancer;Cancers;2024-01-05